Cargando…
The Glasgow prognostic score: Useful information when prescribing palliative radiotherapy
The purpose of the present retrospective study was to investigate whether a score reflecting systemic inflammatory processes [the Glasgow Prognostic Score (GPS)] provides relevant information for radiation oncologists. GPS is a three-tiered score [0: normal C-reactive protein (CRP) and albumin; 1: o...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451880/ https://www.ncbi.nlm.nih.gov/pubmed/28588769 http://dx.doi.org/10.3892/mco.2017.1228 |
_version_ | 1783240264815476736 |
---|---|
author | Nieder, Carsten Mannsåker, Bård Dalhaug, Astrid Pawinski, Adam Haukland, Ellinor |
author_facet | Nieder, Carsten Mannsåker, Bård Dalhaug, Astrid Pawinski, Adam Haukland, Ellinor |
author_sort | Nieder, Carsten |
collection | PubMed |
description | The purpose of the present retrospective study was to investigate whether a score reflecting systemic inflammatory processes [the Glasgow Prognostic Score (GPS)] provides relevant information for radiation oncologists. GPS is a three-tiered score [0: normal C-reactive protein (CRP) and albumin; 1: one abnormal result; 2: increased CRP and low albumin]. Correlations between disease type and extent, resource utilization, survival and GPS were analyzed in 703 patients. In the subgroup with GPS 2, significantly higher rates of lung, adrenal gland and liver metastases were observed. An increasing GPS score was associated with a higher likelihood of anemia, leukocytosis and thrombocytosis. Comparable findings were made regarding utilization of palliative care resources, need for blood transfusion and intravenous administration of antibiotics. Compared with GPS 0 or 1, more patients with GPS 2 did not complete their prescribed course of radiotherapy. One-third of patients with GPS 2 received treatment during the final month of life. Multivariate analysis demonstrated that GPS was a significant prognostic factor for overall survival (median, 479, 136, and 61 days, for GPS 0, 1 and 2, respectively). In patients with GPS 2 and additional leukocytosis, the median survival was 38 days. In conclusion, GPS provides important prognostic information. This biomarker-based score may be considered for deciding fractionation, and should be validated further. |
format | Online Article Text |
id | pubmed-5451880 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-54518802017-06-06 The Glasgow prognostic score: Useful information when prescribing palliative radiotherapy Nieder, Carsten Mannsåker, Bård Dalhaug, Astrid Pawinski, Adam Haukland, Ellinor Mol Clin Oncol Articles The purpose of the present retrospective study was to investigate whether a score reflecting systemic inflammatory processes [the Glasgow Prognostic Score (GPS)] provides relevant information for radiation oncologists. GPS is a three-tiered score [0: normal C-reactive protein (CRP) and albumin; 1: one abnormal result; 2: increased CRP and low albumin]. Correlations between disease type and extent, resource utilization, survival and GPS were analyzed in 703 patients. In the subgroup with GPS 2, significantly higher rates of lung, adrenal gland and liver metastases were observed. An increasing GPS score was associated with a higher likelihood of anemia, leukocytosis and thrombocytosis. Comparable findings were made regarding utilization of palliative care resources, need for blood transfusion and intravenous administration of antibiotics. Compared with GPS 0 or 1, more patients with GPS 2 did not complete their prescribed course of radiotherapy. One-third of patients with GPS 2 received treatment during the final month of life. Multivariate analysis demonstrated that GPS was a significant prognostic factor for overall survival (median, 479, 136, and 61 days, for GPS 0, 1 and 2, respectively). In patients with GPS 2 and additional leukocytosis, the median survival was 38 days. In conclusion, GPS provides important prognostic information. This biomarker-based score may be considered for deciding fractionation, and should be validated further. D.A. Spandidos 2017-06 2017-04-26 /pmc/articles/PMC5451880/ /pubmed/28588769 http://dx.doi.org/10.3892/mco.2017.1228 Text en Copyright: © Nieder et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Nieder, Carsten Mannsåker, Bård Dalhaug, Astrid Pawinski, Adam Haukland, Ellinor The Glasgow prognostic score: Useful information when prescribing palliative radiotherapy |
title | The Glasgow prognostic score: Useful information when prescribing palliative radiotherapy |
title_full | The Glasgow prognostic score: Useful information when prescribing palliative radiotherapy |
title_fullStr | The Glasgow prognostic score: Useful information when prescribing palliative radiotherapy |
title_full_unstemmed | The Glasgow prognostic score: Useful information when prescribing palliative radiotherapy |
title_short | The Glasgow prognostic score: Useful information when prescribing palliative radiotherapy |
title_sort | glasgow prognostic score: useful information when prescribing palliative radiotherapy |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451880/ https://www.ncbi.nlm.nih.gov/pubmed/28588769 http://dx.doi.org/10.3892/mco.2017.1228 |
work_keys_str_mv | AT niedercarsten theglasgowprognosticscoreusefulinformationwhenprescribingpalliativeradiotherapy AT mannsakerbard theglasgowprognosticscoreusefulinformationwhenprescribingpalliativeradiotherapy AT dalhaugastrid theglasgowprognosticscoreusefulinformationwhenprescribingpalliativeradiotherapy AT pawinskiadam theglasgowprognosticscoreusefulinformationwhenprescribingpalliativeradiotherapy AT hauklandellinor theglasgowprognosticscoreusefulinformationwhenprescribingpalliativeradiotherapy AT niedercarsten glasgowprognosticscoreusefulinformationwhenprescribingpalliativeradiotherapy AT mannsakerbard glasgowprognosticscoreusefulinformationwhenprescribingpalliativeradiotherapy AT dalhaugastrid glasgowprognosticscoreusefulinformationwhenprescribingpalliativeradiotherapy AT pawinskiadam glasgowprognosticscoreusefulinformationwhenprescribingpalliativeradiotherapy AT hauklandellinor glasgowprognosticscoreusefulinformationwhenprescribingpalliativeradiotherapy |